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i i lit ri l
W ithout a doubt, driving with the presence of drugs in the body is a real problem asso-ciated with a higher risk of being involved in road traffic collisions. Thus, intervention 
aimed at preventing drug driving is a top priority (Álva-
rez & González-Luque, 2010; DRUID, 2012; Schulze et al., 
2012). 
In this article, we use the concept injuries due to road traffic 
collisions and not the inadequate term, traffic accidents. Most 
injuries resulting from road traffic collisions are preventable 
(Álvarez, 2005; Redelmeier & McLellan, 2013), hence the 
aim of this article: making professionals aware of the fact 
that these injuries are avoidable, particularly professionals 
who treat patients for any Substance Use Disorder (SUD), 
and that they can and should intervene in the prevention 
of injuries due to road traffic collisions. Like the slogan of 
the 2004 World Health Day: “Road safety is no accident” 
(Álvarez, 2005).
When focusing on drugs and road safety, no doubt the 
most dangerous culprit is alcohol. Based on the results 
of the European DRUID project (DRUID, 2012; Schulze 
et al., 2012), intervention in the field of road safety and 
drugs other than alcohol cannot be carried out if it implies 
reducing the amount of alcohol-related interventions 
(Romano, Torres-Saavedra, Voas, & Lacey, 2014). For 
all professionals who work in the field of addictions, 
intervention related to alcohol, drugs and driving should 
be carried out integrally, and under no circumstances 
should alcohol be left out. 
About the Terminology:  
Driving with the Presence of Drugs 
This article includes the term driving with the presence 
of drugs in the body, which means there are quantifiable 
amounts of drugs in the driver´s organism, avoiding the 
term driving under the effect or influence of drugs. Some 
countries practice a zero tolerance policy, that is, any amount 
of drugs detected in the driver´s body is a punishable 
offence, whereas in other cases, a certain concentration 
level is established, a cut-off point, and any amount of 
drugs detected above that level is a driving offence. In 
other cases, impairment is the focus, in which the driver’s 
display of evidence of impairment (driving under the 
influence or effect of drugs)— detected through the use 
of various field sobriety tests (coordination tests, etc.) 
(Álvarez & González-Luque, 2014)— is forbidden, and 
therefore punishable by law.
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Driving with the Presence of Drugs:  
Is it a Real Problem?
Previous studies have shown that driving with the presence 
of drugs is a frequent occurrence (Barlés, Escario, & Galbé, 
2014; EMCDDA, 2007; Verstraete & Legrand, 2014), and the 
results should be analysed taking into account the different 
populations of drivers included in the study (general 
population, offenders, injured or killed drivers).
The European DRUID project (DRUID, 2012; Schulze 
et al., 2012) has provided data for Europe, obtained 
from random roadside testing: in 8.43% (range: 1.34-
15.01%) of the drivers, the presence of alcohol/drugs/
certain medications was confirmed, with large differences 
between countries: Italy (15.01%) and Spain (14.85%) 
were the countries in which drivers testing positive for 
these substances were most frequently found. At the 
European level, without taking into account the association 
between substances, the most frequently detected drug was 
alcohol, followed by cannabis (THC) (1.32%) and cocaine 
(0.42%). The highest prevalence of drivers testing positive 
for cannabis and cocaine was observed in Spaniards. 
Furthermore, it is important to highlight that, of all the 
countries participating in the study, Spain had the highest 
percentage (7.63%) of drivers with the presence of any of 
these drugs. 
According to a recent study (Fierro, González-
Luque, Seguí-Gomez, & Álvarez, 2015) performed using 
representative samples of vehicle drivers in Spain in 2008/9 
and 2013, a decrease was observed in the frequency of 
drivers with the presence of  alcohol (4.92%; 95% CI [4.18, 
5.66] in 2008/9, and 3.41% [2.27, 4.07] in 2013) and drugs 
(6.93% [6.07, 7.80] in 2008/9, and 4.87% [4.09, 5.65] in 
2013). The decrease in positive cases for drugs is, to a great 
measure, due to a decrease in the positive cases for cannabis. 
The routine use of roadside drug controls may have been a 
contributing factor in this respect.
Drugs and the Risk of  
Road Traffic Collisions
Currently, preventive interventions should be developed 
on the basis of scientific evidence. For this purpose, one 
of the priorities of the European DRUID projects was to 
analyse the risk involved in drug driving (serious injuries or 
deaths)(DRUID, 2012; Schulze et al., 2012). 
Four risk levels were established to interpret the results:
Slight increase in risk (RR=1-3): Risk associated with driving 
with a blood alcohol concentration between 0.1 and <0.5 
g/L, and with the presence of cannabis.
Medium increase in risk (RR=2-10): Driving with a blood 
alcohol concentration between 0.5 g/L and < 0.8 g/L, or 
with the presence of cocaine, illegal and medicinal opiates, 
benzodiazepines, and Z-hypnotics (without mixing one 
drug group with another).
High increase in risk (RR=5-30): Driving with a blood alcohol 
concentration between 0.8 and <1.2 g/L, as well as the 
presence of amphetamines and a mixture of different drugs.
Extremely high increase in risk (RR=20-200): Driving with 
a blood alcohol concentration ≥ 1.2 g/L, and with the 
simultaneous presence of alcohol and drugs. 
The data showed that driving with the presence of alcohol 
(blood alcohol concentration ≥0.8 g/L) in combination 
with other drugs or multi-drug consumption (alcohol + 
drugs or an association of drugs) correlates with a higher 
risk of road traffic collisions.
Most of the available information is about cannabis, 
which could be used to establish a relationship between 
concentration and risk (Asbridge, Hayden, & Cartwright, 
2012; Laumon et al., 2006; Verstraete & Legrand, 2014). 
Recently, Elvik (2013) and Verstraete & Legrand (2014) 
have updated the available information related to alcohol, 
drugs and certain types of medicines and risk of road traffic 
collisions. 
Driving with the presence of Drugs:  
Legal Issues
In most countries, driving with the presence of drugs is an 
offence (EMCDDA, 2015). In the case of Spain, it is regulated 
as an offense in the administrative area, as well as a crime 
under criminal law, although both sanctions cannot occur 
simultaneously. The model differentiates between “presence” 
and the abstract danger referred to in administrative laws 
(zero tolerance criterion) and “influence” (impairment 
criterion) and the specific danger stipulated by the Penal 
Code (Álvarez & González-Luque, 2014).
Recently, Spanish legislation has introduced relevant 
changes (Ley 6/2014) involving:
- The prohibition of driving with the presence of drugs 
in the body, in other words, the “zero tolerance” princi-
ple in the matter of drugs and driving.
- Consideration of the Saliva Test, using an authorized 
device as the preferred way to detect the presence of 
drugs in the person’s body in situ and as the chosen 
means of post-analysis confirmation.
- The fine for driving with the presence of drugs in the 
person’s body, or for refusing to undergo the detection 
tests, is established at €1,000, along with the loss of 6 
driver’s licence points.
Roadside Tests for the Detection of Drugs: 
Saliva versus Blood 
Until the present, and due to great extent to the legal 
and practical issues of taking blood samples, performing 
roadside tests to detect the presence of drugs in drivers 
was unusual. Currently, however, it is possible to detect the 
presence of drugs in saliva samples, or more specifically 
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“oral fluid,” through non-invasive methods. These systems 
are already available and are being used on a routine basis. 
Although there are some limitations, especially in relation 
to sensitivity, specificity, and cut-off values (Verstraete, 
2005), drug detection through oral fluid is reliable when 
the roadside test is linked to a subsequent laboratory 
confirmation analysis, as in the case of Spanish legal 
regulations.     
Different devices are used for roadside testing; currently, 
in the case of Spain, the Dräger DrugTest® 5000, DrugWipe®, 
and Alere™ DDS®2 Mobile Test System are being employed. 
With these devices, various types of substances can be 
detected: cannabis, opiates, cocaine, amphetamines and 
their analogues, benzodiazepines, etc. These devices detect 
the active substance in the person’s oral fluid, confirming 
the recent use of the drug. 
Project DRUID established a core list of detectable 
substances (27) and their cut-off values for the confirmatory 
tests and quantification with chromatography, with the 
principle aim of using them in epidemiological studies. 
The available information about substance concentration 
equivalence in blood and saliva (oral fluid) is limited, and 
the information from the Project DRUID is currently used 
as a reference (DRUID, 2012; Schulze et al., 2012). Recently, 
equivalences of blood and oral fluid have been proposed for 
12 key substances (Gjerde, Langel, Favretto, & Verstraete, 
2014).
The practice of performing drug tests on drivers’ oral 
fluid is already being adopted in developed countries.
What Can Health Professionals Do?
So far, in this article, we have only referred to drivers 
in general as well as driving with the presence of drugs. 
However, professionals who treat addictions attend to 
patients with SUD (Substance Use Disorder). Why is driving 
important for these professionals and relevant to their 
clinical practice? Why should they intervene actively?
1. Do Our SUD Patients Drive?
Previous studies (Álvarez, Gómez-Talegón, & Marcos, 
2010) have indicated that SUD patients frequently drive, 
and data from the multi-centre Spanish study, PROTEUS 
(Roncero et al., 2013) have confirmed that: a significant 
percentage (52%) of opiate dependent patients (in 
treatment) drive. Ninety-four percent of those patients 
were being treated, with average doses of 60 mg/day of 
methadone. At this level of dosage, methadone interferes—
or could potentially interfere—with driving. The patients 
who drove were found to have fewer legal problems, which 
could be explained by the fact that driving may be a part 
of the “normalization” process for the patient and, in some 
cases, indispensable for professional activity. Therefore, it is 
important to ensure these patients can drive safely. 
2. SUD Patients, Neuropsychological Deficits and 
Driving Ability 
Regular drug use is associated with deficits in various 
neuropsychological domains or areas. Furthermore, SUD 
patients frequently present medical comorbidity and 
psychiatric comorbidity. Finally, SUD patients receive 
specific treatment for their addiction, commonly including 
adjunctive psychopharmacological treatment, which could 
interfere with psychomotor performance and adequate 
driving fitness. 
Within the global treatment/re-integration process of 
SUD patients, the following three aspects should be taken 
into account: (a) the disease itself, the addiction, and the 
neuropsychological deficits; (b) comorbidity; and (c) the 
pharmacological treatment (Baldaccino et al., 2012; Lorea 
et al., 2011; Lundqvist, 2005; Soler, Balcells, & Gual, 2014).
European legislation (CD 439/1991/EEC) and Spanish 
legislation (Real Decreto 818/2009) establish the minimum 
requirements when assessing driving fitness. In the case of 
Spain, testing driving fitness is carried out at the Medical 
Driver Test Centres (in Spanish, Centros de Reconocimiento 
de Conductores, hereafter, CRC). Being diagnosed with 
SUD does not in itself indicate a deterioration of driving 
fitness. In any case, evaluation of drivers with SUD must 
be performed individually in the above-mentioned centres 
along with a necessary medical report about the patient.
The assessment of driving fitness and reports to the CRC 
are problematic in clinical practice. Sometimes, the health 
professional must present a report about the patient to the 
CRC, either at the request of the patient, the CRC itself, or 
the authorities. The role of the health professional treating 
these patients does not include determining whether or 
not the patient can drive, but rather reporting the patient’s 
clinical status. The patient’s analysis must include: diagnosis, 
patient‘s treatment adherence, dates of remissions or 
relapses, suicide risk and behaviour, length of time in a 
stable condition, and possible side-effects of the medication 
involved, and whether or not the patient consumes other 
types of drugs (for example, results of urine analyses, etc.) 
(Álvarez & González-Luque, 2014).
Another issue related to, yet independent from, the 
above-mentioned aspect of assessing driving fitness is the 
medical advice that must be offered to the patient at every 
visit to the doctor, in particular, whether or not the patient 
should drive, or whether the patient should limit his/her 
driving activity, all based on the patient’s clinical state. These 
aspects will be analysed in greater detail in section 6.
3. Do SUD Patients Run a Higher Risk of Road Tra-
ffic Collisions?
Drivers with certain psychiatric pathologies present a 
higher risk of road traffic collisions than healthy drivers. 
In a meta-analysis (Vaa, 2003) in which the risk of traffic 
collisions was analysed in relation to the medical and 
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neuropsychiatric disorders outlined by the European 
Directive CD 91/439/EEC, having a mental disorder was 
one of the conditions with the highest risk of suffering a 
road traffic collision (RR= 1.72, 95% CI [1.48, 1.99]), along 
with alcohol abuse or dependency (RR = 2.00, 95% CI 
[1.89,  2.12]) and drug abuse or dependency (RR = 1.58, 
95%, CI [1.45, 1.73]).
On the other hand, many studies (Álvarez, Gómez-
Talegón, & Marcos, 2010; Gomes et al., 2013) have shown 
that patients with SUD have more accidents in general, 
not only road traffic collisions, and that the road traffic 
collisions contribute to a higher mortality rate in this group 
of patients, even if the accidents are not the main cause of 
death (Degenhardt el al., 2014).
4. Prescription Drugs for SUD Patients and Driving 
The use of pharmaceuticals to treat underlying 
pathologies (SUD) and medical and psychiatric comorbidity 
leads to frequent use of prescription drugs in these patients, 
as mentioned above. 
Of the medicines authorized in the treatment of addictions, 
bupropion, varenicline, naltrexone, buprenorphine, and 
methadone include the pictogram warning of driving-
impairing medicines in Spain (Fierro, Gómez-Talegón, & 
Álvarez, 2013), whereas nicotine, acamprosate, carbamide, 
disulfiram, or nalmefene do not include such a pictogram 
(AEMPS, 2015; Álvarez & González-Luque, 2014). However, 
the summary of product characteristics and patient 
information leaflets include information about the effect of 
these medications on driving (Ravera et al., 2012). 
Although the pictogram’s purpose is only to inform, one 
should pay attention to the fact that it is present and always 
make the patient aware of this, especially when the majority 
of SUD patients are undergoing treatment with psychotropic 
drugs: of the 198 active substances authorized in group N in 
Spain, 180 include a pictogram concerning medicines and 
driving on the package (AEMPS, 2015; Álvarez & González-
Luque, 2014).
Recently, patients in maintenance programs with an 
opioid agonist (methadone and buprenorphine) and who 
drive vehicles have been the focus of attention (Strand, 
Fjeld, Arnestad & Morland, 2013; Soyka, 2014). Both 
medicines can affect a person’s ability to drive safely, and 
this information is provided in the summary of product 
characteristics, patient information leaflets, and also 
shown in the driving-impairing medicines pictogram on 
the medicine package in the case of Spain. Buprenorphine 
has been shown to have some advantages (Roncero et al., 
2013), for example, the deterioration of the psychomotor 
performance of opiate dependent SUD patients is lower 
than for methadone (Rapeli, Fabritius, Kalska & Alho, 2011; 
2012).
The key factors are the pathology, the neuropsychological 
deficits and the medical and psychiatric comorbidity. 
Medication is an added factor: it could interfere negatively 
at the beginning of treatment, but as the patients improve 
their clinical situation, the effect may be positive. Special 
attention should be paid to prescription drugs for these 
particular patients and the possibility of drug interactions 
that could consequently increase the sedative effects on 
the central nervous system, anticholinergic effects, and 
effects on vision. The consumption of alcohol and other 
drugs should also be avoided (Álvarez & González-Luque, 
2014).
Furthermore, health professionals should inform their 
patients, especially in the area of addictions, about which 
medications (opiates, benzodiazepines, etc.) could screen 
positive in roadside drug testing.
5. Treatment Reduces the Rate of Traffic Accidents 
in SUD Patients
There is increasing evidence that treatment programs 
for SUD patients help to reduce their involvement in road 
traffic collisions (Darke, Kelly, & Ross, 2004; Gómez-Talegón 
& Álvarez, 2006). 
A Norwegian study (Bukten et al., 2013) spanning 9 
years, in which data was collected before, during and after 
treatment on collisions and road traffic infractions specific 
to patients being treated with substitute opiates, observed 
that these particular patients reduced road traffic collisions 
and infractions by 40%.
6. Drugs, Addictions, and Driving: Information and 
Advice Given to Patients with SUD
We now present the key points, in our opinion, 
concerning information and medical/healthcare advice for 
patients with SUD.
- Based on scientific evidence about SUD patients and 
driving (change in behaviour at the wheel and road 
rage; Benavidez, Flores, Fierro, & Álvarez, 2013), fre-
quent involvement in road traffic collisions and other 
types of injuries (Álvarez, Gómez-Talegón, & Marcos, 
2010; Coghlan & Macdonald, 2010; Darke, Kelly, & 
Ross, 2004; Macdonald et al., 2004), and a higher risk 
of road traffic collisions (Schulze et al., 2012; Verstrae-
te & Legrand, 2014)), patients should be fully infor-
med that if they drive with the presence of drugs, they 
are choosing high risk behaviour not only for themsel-
ves but for other people on the road (Álvarez & Gon-
zález-Luque, 2010; 2014).
- Patients should be informed that illnesses, comorbidity, 
etc., and the side- effects of medication can influence 
their ability to drive safely. In this regard, studies have 
supported the fact that doctors’ advice to patients who 
are potentially unfit to drive helps reduce traffic colli-
sions (Redelmeier et al., 2012).
- Prescribing medication that interferes less with psycho-
motor performance is a top priority. It is also impor-
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tant to avoid and prevent pharmacodynamic interac-
tions that intensify sedative side-effects, anticholinergic 
side-effects and vision impairment. To this end, the 
patient should also be informed that he/she should 
not consume alcohol and/or drugs, not only to avoid 
driving with the presence of drugs, but also to avoid 
possible interactions with the different medications.
- Patients should be informed that treatment not only 
improves their pathological processes but is also asso-
ciated with less frequent involvement in road traffic 
collisions.
- Furthermore, patients must be informed that the de-
vices currently used in roadside testing detect the pre-
sence of drugs and certain medicines (opiates, benzo-
diazepines, etc.) in saliva, and, in the case of positive 
detection, the individual will be penalized. In Spain, 
a future regulation to avoid the sanction is foreseen if 
the patient is undergoing medical treatment and fulfils 
certain criteria.
An important aspect is the advice or recommendation 
of whether or not to drive: no doubt, the most critical 
moments are at the start of the treatment. Patients 
should be told not to drive, or to limit driving as much 
as possible (only short journeys, frequent rests, etc.). This 
recommendation should be updated at every visit at the 
beginning of the treatment, according to the clinical 
evolution of each patient. Adequate information will allow 
the patient to be aware of the risk both to him/herself and 
to other road users.
Another aspect is whether or not the patient is fit to drive 
(see point 2). This should be evaluated by the competent 
organism, in the case of Spain, by the CRC. In any case, 
this does not mean that, as health professionals, we should 
not inform the patient with SUD when necessary and 
recommend not driving or performing other activities that 
may pose a risk.
A triptych including some aspects that SUD patients should 
know about drugs and driving has been created (Álvarez & 
González-Luque, 2014).
Conclusion
Operating a vehicle is a good prognostic factor for the 
social integration of an SUD patient, and interventions 
should be developed for their implementation, favouring 
and encouraging these patients to drive safely under 
medical-psychological supervision. Health professionals 
should be actively involved, informing their patients and 
giving them advice (Redelmeier & Tien, 2014) as well as 
choosing the correct medication to prescribe. 
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